127 related articles for article (PubMed ID: 38636197)
21. From 2646 to 15: differentially regulated microRNAs between progenitors from normal myometrium and leiomyoma.
Lazzarini R; Caffarini M; Delli Carpini G; Ciavattini A; Di Primio R; Orciani M
Am J Obstet Gynecol; 2020 Jun; 222(6):596.e1-596.e9. PubMed ID: 31874141
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids.
Pan Q; Luo X; Chegini N
J Cell Mol Med; 2008; 12(1):227-40. PubMed ID: 18182067
[TBL] [Abstract][Full Text] [Related]
23. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
24. [Progress in clinicopathologic study on uterine smooth muscle tumor of uncertain malignant potential].
Deng ZJ; Guo LN
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):573-6. PubMed ID: 22169655
[No Abstract] [Full Text] [Related]
25. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.
Bertsch E; Qiang W; Zhang Q; Espona-Fiedler M; Druschitz S; Liu Y; Mittal K; Kong B; Kurita T; Wei JJ
Mod Pathol; 2014 Aug; 27(8):1144-53. PubMed ID: 24390224
[TBL] [Abstract][Full Text] [Related]
26. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
27. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
[TBL] [Abstract][Full Text] [Related]
28. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
[TBL] [Abstract][Full Text] [Related]
29. The regulatory function of miR-200c on inflammatory and cell-cycle associated genes in SK-LMS-1, a leiomyosarcoma cell line.
Chuang TD; Ho M; Khorram O
Reprod Sci; 2015 May; 22(5):563-71. PubMed ID: 25305131
[TBL] [Abstract][Full Text] [Related]
30. The role of fibroblast growth factor 2 in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Mayerhofer K; Czerwenka K; Kimberger O; Koelbl H; Bodner K
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():62-67. PubMed ID: 27825029
[TBL] [Abstract][Full Text] [Related]
31. Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas.
Zavadil J; Ye H; Liu Z; Wu J; Lee P; Hernando E; Soteropoulos P; Toruner GA; Wei JJ
PLoS One; 2010 Aug; 5(8):e12362. PubMed ID: 20808773
[TBL] [Abstract][Full Text] [Related]
32. Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma.
Loddenkemper C; Mechsner S; Foss HD; Dallenbach FE; Anagnostopoulos I; Ebert AD; Stein H
Am J Surg Pathol; 2003 Nov; 27(11):1458-62. PubMed ID: 14576480
[TBL] [Abstract][Full Text] [Related]
33. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
34. Inguinal smooth muscle tumors in women-a dichotomous group consisting of Müllerian-type leiomyomas and soft tissue leiomyosarcomas: an analysis of 55 cases.
Patil DT; Laskin WB; Fetsch JF; Miettinen M
Am J Surg Pathol; 2011 Mar; 35(3):315-24. PubMed ID: 21297441
[TBL] [Abstract][Full Text] [Related]
35. Reduced expression of calponin h1 in leiomyosarcoma of the uterus.
Horiuchi A; Nikaido T; Ito K; Zhai Y; Orii A; Taniguchi S; Toki T; Fujii S
Lab Invest; 1998 Jul; 78(7):839-46. PubMed ID: 9690561
[TBL] [Abstract][Full Text] [Related]
36. Molecular prognostication of uterine smooth muscle neoplasms: From CGH array to CINSARC signature and beyond.
Croce S; Chibon F
Genes Chromosomes Cancer; 2021 Mar; 60(3):129-137. PubMed ID: 33099852
[TBL] [Abstract][Full Text] [Related]
37. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy.
Danielson LS; Menendez S; Attolini CS; Guijarro MV; Bisogna M; Wei J; Socci ND; Levine DA; Michor F; Hernando E
Am J Pathol; 2010 Aug; 177(2):908-17. PubMed ID: 20558575
[TBL] [Abstract][Full Text] [Related]
38. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
[TBL] [Abstract][Full Text] [Related]
39. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma.
Ravegnini G; Mariño-Enriquez A; Slater J; Eilers G; Wang Y; Zhu M; Nucci MR; George S; Angelini S; Raut CP; Fletcher JA
Mod Pathol; 2013 May; 26(5):743-9. PubMed ID: 23222489
[TBL] [Abstract][Full Text] [Related]
40. Pathology, cytogenetics and molecular biology of uterine leiomyomas and other smooth muscle lesions.
Quade BJ
Curr Opin Obstet Gynecol; 1995 Feb; 7(1):35-42. PubMed ID: 7742513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]